Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells 11,000 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 11,000 shares of the company’s stock in a transaction dated Wednesday, November 26th. The stock was sold at an average price of $486.06, for a total transaction of $5,346,660.00. Following the transaction, the executive vice president owned 36,781 shares of the company’s stock, valued at approximately $17,877,772.86. This trade represents a 23.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

United Therapeutics Trading Up 0.5%

UTHR stock traded up $2.66 during midday trading on Wednesday, reaching $488.43. The stock had a trading volume of 329,977 shares, compared to its average volume of 588,336. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $492.62. The company has a market cap of $21.03 billion, a price-to-earnings ratio of 18.51, a price-to-earnings-growth ratio of 4.96 and a beta of 0.77. The company’s fifty day simple moving average is $443.02 and its 200 day simple moving average is $358.73.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping the consensus estimate of $6.89 by $0.27. The business had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.During the same quarter in the previous year, the firm earned $6.39 EPS. The company’s quarterly revenue was up 6.8% compared to the same quarter last year. Sell-side analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

Institutional Trading of United Therapeutics

A number of large investors have recently made changes to their positions in UTHR. Chung Wu Investment Group LLC acquired a new position in shares of United Therapeutics in the second quarter valued at approximately $29,000. WealthCollab LLC raised its holdings in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. grew its stake in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares during the period. SVB Wealth LLC purchased a new stake in shares of United Therapeutics in the first quarter worth about $32,000. Finally, Wilmington Savings Fund Society FSB boosted its stake in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on UTHR shares. Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a research report on Wednesday, October 29th. Cantor Fitzgerald increased their price target on United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research report on Wednesday, September 10th. Oppenheimer upped their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. Weiss Ratings reissued a “buy (b-)” rating on shares of United Therapeutics in a research report on Tuesday. Finally, Bank of America lifted their target price on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 2nd. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $505.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.